Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1236-1244

  Dahut, W ^a   Harold, N ^a   Takimoto, C ^a   Allegra, C ^a   Chen, A ^a   Hamilton, J M ^a   Arbuck, S ^a   Sorensen, M ^a   Grollman, F ^a   Nakashima, H ^a   Lieberman, R ^a   Liang, M ^a   Corse, W ^a   Grem, J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA;

EID: 9244231199     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1236     Document Type: Article

References (26)

1. Slichenmyer WR, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
2. Potmesil M: Camptothecins from bench research to hospital wards. Cancer Res 54:1431-1439, 1994
3. Burns HA, Fields SM: Topoisomerase I inhibitors: an overview of the camptothecin analogs. Hematol Oncol Clin North Am 8:333-355, 1994
4. Takimoto CH, Arbuck SG: The camptothecins, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 2). Philadelphia, PA, Lippincott-Raven, 1996, pp 463-484
5. Gottlieb JA, Guarino AM, Call JB, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461-470, 1970
6. Muggia FM, Creaven PJ, Hansen HH, et al: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 54:515-521, 1972
7. Gottlieb JA, Luce JK: Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56:103-105, 1972
8. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
9. Pantazis P, Hinz HR, Mendoza JT, et al: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52:3980-3987, 1992
10. Fassberg J, Stella VJ: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676-684, 1992
11. Hertzberg RP, Caranfa MJ, Holden, et al: Modification of the hydroxy lactone ring of camptothecins: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715-720, 1989
12. Takimoto CH, Klecker RW, Dahut W, et al: Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr 655:97-104, 1994
13. Grem JL, Jordan E, Robson ME, et al: Phase II study of fluorouracil, leucovorin, and interferon alpha-2a in metastatic colorectal carcinoma. J Clin Oncol 11:1737-1745, 1993
14. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Dekker, 1982
15. Yamaoka K, Tanigawara Y, Nakagawa T, et al: A pharmacokinetic analysis program (MULTI) for microcomputers. J Pharmacobiodyn 4:879-885, 1981
16. Rowland M, Tozer T: Clinical Pharmacokinetics: Concepts and Applications (ed 2). Philadelphia, PA, Lea & Febiger, 1989
17. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokin Biopharm 6:165-175, 1978
18. Rothenberg ML, Kuhn JG, Burris HA, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
19. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
20. Blaney SM, Balis FM, Cole DE, et al: Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 53:1032-1036, 1993
21. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) administered as a 90 minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
22. Rivory LP, Chateleut E, Canal P, et al: Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 54:6330-6333, 1994
23. Burke TG, Mi Z: Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J Med Chem 36:2580-2582, 1993
24. Grochow LB, Rowinsky EK, Johnson R, et al: Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706-713, 1992
25. Haas NB, LaCreta FP, Walczak J, et al: Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 54:1220-1226, 1994
26. Rubin E, Wood V, Bharti A, et al: A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1:269-276, 1995